Hsa-Mir-320c, Hsa-Mir-200c-3p, and Hsa-Mir-449c-5p as Potential Specific miRNA Biomarkers of COPD: A Pilot Study

被引:11
|
作者
Ceron-Pisa, Noemi [1 ]
Iglesias, Amanda [1 ,2 ]
Shafiek, Hanaa [3 ]
Martin-Medina, Aina [1 ]
Esteva-Socias, Margalida [4 ]
Muncunill, Josep [1 ]
Fleischer, Aarne [1 ]
Verdu, Javier [1 ,5 ]
Cosio, Borja G. G. [1 ,2 ,5 ]
Sauleda, Jaume [1 ,2 ,5 ]
机构
[1] Inst Invest Sanit Illes Balears IdISBa, Palma De Mallorca 07120, Spain
[2] Ctr Invest Biomed Red Resp Dis CIBERES, Madrid 28029, Spain
[3] Alexandria Univ, Fac Med, Chest Dis Dept, Alexandria 21526, Egypt
[4] Umea Univ, Wallenberg Ctr Mol Med, Dept Mol Biol, S-90187 Umea, Sweden
[5] Hosp Univ Son Espases, Resp Med, Palma De Mallorca 07120, Spain
关键词
lung disease; COPD; miRNAs; biomarker; MACROPHAGE ACTIVATION; MICRORNA EXPRESSION; EPITHELIAL-CELLS; DISEASE; ROLES;
D O I
10.3390/pathophysiology29020013
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease commonly induced by cigarette smoke. The expression of miRNAs can be altered in patients with COPD and could be used as a biomarker. We aimed to identify a panel of miRNAs in bronchoalveolar lavage (BAL) to differentiate COPD patients from smokers and non-smokers with normal lung function. Accordingly, forty-five subjects classified as COPD, smokers, and non-smokers (n = 15 per group) underwent clinical, functional characterization and bronchoscopy with BAL. The mean age of the studied population was 61.61 +/- 12.95 years, BMI 25.72 +/- 3.82 Kg/m(2), FEV1/FVC 68.37 +/- 12.00%, and FEV1 80.07 +/- 23.63% predicted. According to microarray analysis, three miRNAs of the most upregulated were chosen: miR-320c, miR-200c-3p, and miR-449c-5p. These miRNAs were validated by qPCR and were shown to be differently expressed in COPD patients. ROC analysis showed that these three miRNAs together had an area under the curve of 0.89 in differentiating COPD from controls. Moreover, in silico analysis of candidate miRNAs by DIANA-miRPath showed potential involvement in the EGFR and Hippo pathways. These results suggest a specific 3-miRNA signature that could be potentially used as a biomarker to distinguish COPD patients from smokers and non-smoker subjects.
引用
收藏
页码:143 / 156
页数:14
相关论文
共 50 条
  • [1] Exosome-derived hsa-miR-200c-3p, hsa-miR-25-3p and hsa-miR-301a-3p as potential biomarkers and therapeutic targets for restoration of PTEN expression in clear cell renal cell carcinoma
    Alves, Angela
    Ferreira, Mariana
    Eiras, Mariana
    Lima, Luis
    Medeiros, Rui
    Teixeira, Ana Luisa
    Dias, Francisca
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2025, 302
  • [2] Hsa-let-7c-5p, hsa-miR-130b-3p, and hsa-miR-142-3p as Novel miRNA Biomarkers for Melanoma Progression
    Wu, Xuerui
    Wang, Yu
    Chen, Chen
    Xue, Yadong
    Zheng, Shuyun
    Cai, Limin
    GENETICS RESEARCH, 2022, 2022
  • [3] hsa-miR-1-3p and hsa-miR-361-3p as potential biomarkers for onychomycosis: A pilot study
    Meng, Li
    Cai, Qing
    Zhang, Huaijian
    Gao, Zhiqin
    Yang, Lianjuan
    BIOMEDICAL REPORTS, 2025, 22 (02)
  • [4] The role of exosomal hsa-miR-125b-5p and hsa-miR-320c as non-invasive biomarkers in high-radon areas of Kazakhstan
    Aripova, Akmaral
    Kussainova, Assiya
    Ibragimova, Milana
    Bulgakova, Olga
    Bersimbaev, Rakhmetkazhi
    BIOMARKERS, 2025, 30 (02) : 123 - 130
  • [5] CeRNA network identified hsa-miR-17-5p, hsa-miR-106a-5p and hsa-miR-2355-5p as potential diagnostic biomarkers for tuberculosis
    Song, Jie
    Sun, Jiaguan
    Wang, Yuqing
    Ding, Yuehe
    Zhang, Shengrong
    Ma, Xiuzhen
    Chang, Fengxia
    Fan, Bingdong
    Liu, Hongjuan
    Bao, Chenglan
    Meng, Weimin
    MEDICINE, 2023, 102 (11)
  • [6] Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study
    Casabonne, Delphine
    Benavente, Yolanda
    Seifert, Julia
    Costas, Laura
    Armesto, Maria
    Arestin, Maria
    Besson, Caroline
    Hosnijeh, Fatemeh S.
    Duell, Eric J.
    Weiderpass, Elisabete
    Masala, Giovanna
    Kaaks, Rudolf
    Canzian, Federico
    Chirlaque, Maria-Dolores
    Perduca, Vittorio
    Mancini, Francesca R.
    Pala, Valeria
    Trichopoulou, Antonia
    Karakatsani, Anna
    La Vecchia, Carlo
    Sanchez, Maria-Jose
    Tumino, Rosario
    Gunter, Marc J.
    Amiano, Pilar
    Panico, Salvatore
    Sacerdote, Carlotta
    Schmidt, Julie A.
    Boeing, Heiner
    Schulze, Matthias B.
    Barricarte, Aurelio
    Riboli, Elio
    Olsen, Anja
    Tjonneland, Anne
    Vermeulen, Roel
    Nieters, Alexandra
    Lawrie, Charles H.
    de Sanjose, Silvia
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (05) : 1315 - 1324
  • [7] Expression Analysis of hsa-miR-181a-5p, hsa-miR-143-3p, hsa-miR-132-3p and hsa-miR-23a-3p as Biomarkers in Colorectal Cancer-Relationship to the Body Mass Index
    Tesolato, Sofia Elena
    Gonzalez-Gamo, Daniel
    Barabash, Ana
    Claver, Paula
    de la Serna, Sofia Cristina
    Dominguez-Serrano, Inmaculada
    Dziakova, Jana
    de Juan, Carmen
    Torres, Antonio Jose
    Iniesta, Pilar
    CANCERS, 2023, 15 (13)
  • [8] Downregulation of Circulating Hsa-miR-200c-3p Correlates with Dyslipidemia in Patients with Stable Coronary Artery Disease
    Vancheri, Chiara
    Morini, Elena
    Prandi, Francesca Romana
    Barilla, Francesco
    Romeo, Francesco
    Novelli, Giuseppe
    Amati, Francesca
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (02)
  • [9] Circulating hsa-miR-30e-5p, hsa-miR-92a-3p, and hsa-miR-223-3p may be novel biomarkers in systemic lupus erythematosus
    Kim, B. -S.
    Jung, J. -Y.
    Jeon, J. -Y.
    Kim, H. -A.
    Suh, C. -H.
    HLA, 2016, 88 (04) : 187 - 193
  • [10] Circulating hsa-miR-30e-5p, hsa-miR-92a-3p and hsa-miR-223-3p may be novel biomarkers for Systemic lupus erythematosus
    Suh, C.
    Jung, J.
    Kim, H.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (03) : S22 - S22